Take­da opens cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty — tucked right in its Boston R&D hub

When Take­da un­veiled its trans­la­tion­al cell ther­a­py en­gine ear­ly last year, the Japan­ese phar­ma made it clear the crew, un­der No­var­tis vet Ste­fan Wildt, is go­ing all the way: clin­i­cal ex­per­tise, bio­engi­neer­ing chops, world-class col­lab­o­ra­tions, plus chem­istry, man­u­fac­tur­ing and con­trol.

The fi­nal piece of the puz­zle has now fall­en in place, with the open­ing of a 24,000 square-foot cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty at its R&D head­quar­ters in Boston.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER